桑志培 博士 副教授 博士/硕士生导师 海南自由贸易港高层次人才

邮箱：sangzhipei@hainanu.edu.cn

一、教育背景及工作经历

2022.08-至今 海南大学药学院，副教授

2021.11-2024.11 上海中医药大学，博士后

2019-05至2020-06，新加坡南洋理工大学，博士后

2010-09至2015-06，四川大学华西药学院，硕博连读

2006-09至2010-07，贵州医科大学，药学，学士

二、科研情况

目前研究方向聚焦于人工智能驱动的全新药物设计、成药性优化及作用机制研究”。主持国家自然科学基金、海南省自然科学基金高层次人才项目、中国博士后科学基金面上项目等10项基金，并在Acta Pharm Sin B, J Med Chem, Chinese Chem Lett, Eur J Med Chem, J Agric Food Chem等学术期刊发表论文100余篇，其中以第一或/和通讯作者发表SCI论文62篇（中科院一区18篇，二区19篇，IF大于5的SCI论文32篇）；参与ELSEVIER出版AD领域英文专著2部；以第一发明人获得授权发明专利27项（转让1项），实用新型专利5项。自2023年来，荣获第五届海南大学教师教学创新大赛二等奖；指导本科生以共同第一作者发表SCI论文4篇；获批海南大学大学生创新训练计划项目国家级2项、省级1项；在第十二届“挑战杯”海南省大学生课外学术科技作品竞赛中荣获“特等奖”、“二等奖”各1项，并在第十九届“挑战杯”全国赛中赢得“三等奖”，等等。

三、研究领域

(1) 人工智能驱动的全新药物设计、成药性优化及作用机制研究

(2) 人工智能驱动的天然活性小分子的发现及活性评价

四、社会兼职

(1) 中国药学会老年药学专业委员会委员

(2) 《药学学报》中、英文两刊青年编委

(3) 《Chinese Chemical Letters》(中国化学快报）青年编委会委员

(4) 《Medicinal Plant Biology》青年编委

(5) 《Marine drugs》期刊的Guest Editor

(6) Advanced Science, Chemical Science, Acta Pharm Sin B, J Med Chem, Chinese Chem Lett, Eur J Med Chem, J Agric Food Chem等期刊杂志审稿人

五、代表性项目

(1) 国家自然科学基金，“新型腺嘌呤类PDE8高选择性抑制剂的设计、类药性优化及抗阿尔茨海默症作用研究”，2026.01-2029.12，主持

(2) 国家自然科学基金，“选择性丁酰胆碱酯酶抑制剂的设计、类药性优化及抗AD作用机制研究”，2024.01-2027.12，主持

(3) 海南省自然科学基金高层次人才项目，“丁酰胆碱酯酶选择性抑制剂的合理设计、成药性优化及抗阿尔茨海默症作用研究”，2024.01-2025.12，主持

(4) 海南大学科研启动基金项目，“靶向PDE4的新型抗AD药物研究”，2022.09-2026.12，主持

(5) 中国博士后科学基金第71批面上项目二等资助，“人羧酸酯酶2A特异性共价抑制剂的设计研发、成药性优化及药效学研究”，2022.01-2023.12，主持。

(6) 贵州医科大学 省部共建药用植物功效与利用国家重点实验室开放课题，“杜仲中新型多肽的制备及其活性评价”，2022.01-2023.12，主持。

(7) 贵州医科大学 化学合成药物研发利用工程技术研究中心开放课题，“具有诱导自噬作用的cGN14细胞穿膜环肽的设计、合成及其抗AD活性研究”，2021.08-2022.07，主持。

(8) 河南省科技厅科技攻关项目，“裕丹参中新型多肽的发现及药理活性研究”，2021.01-2022.12，主持

(9) 2020年河南省高等学校重点科研项目，“基于脑靶向的新型高选择性BuChE抑制剂的设计、合成及其抗阿尔茨海默病活性研究”，2020.01-2021.12，主持

(10) 2019年河南省高层次人才国际化培养项目，“口服植物活性肽的研究”，2019.05-2020.06，主持

(11) 河南省自然科学基金，“基于Aβ/AChE双靶点策略的查尔酮衍生物的设计、合成与抗阿尔茨海默病活性研究”，2016.01-2017.12，主持

(12) 2017年河南省高等学校重点科研项目计划，“新型多靶点抑制剂的设计、合成及抗阿尔茨海默症活性研究”，2017.01-2018.12，主持

六、代表性成果（#表示为共同第一，*表示为通讯作者）

6.1 代表性论文（2020年至今）

(1) Shuheng Huang^#, Wenling Fu^#, Ma Chunhua^#, Ya Zhang, Chanchan Liang, Yuting Li, Qiyao Zhang, Haopeng Sun^*, Tao Zhang^*, Guang-Bo Ge^*, Zhipei Sang^*. Skeleton constraint-driven development of novel butyrylcholinesterase inhibitors for treating Alzheimer's disease. Nature Communications, 2025 (Under review)

(2) Zhipei Sang^#, Ya Zhang^#, Yufan Fan^#, Wenling Fu, Changhai Luan, Chanchan Liang, Hairong Zeng*, Shuheng Huang*, Guang-Bo Ge*. Artificial intelligence-driven development of novel hCES2A covalent inhibitors for treating irinotecan-triggered gut toxicity. Science Bulletin, 2025 (Under review)

(3) Zheng Li^#, Wanting Huan^#, Xingfu Liu^#, Kai Zhang, Xue Wang, Yiyou Huang, Qian Zhou, Shuheng Huang^*, Zhipei Sang^*, Haibin Luo^*. Artificial intelligence-driven discovery of pyrazolo[1,5-a]pyrimidine derivatives as novel phosphodiesterase 4 inhibitors for treating idiopathic pulmonary fibrosis. Journal of Medicinal Chemistry, 2025, Nov 18. doi: 10.1021/acs.jmedchem.5c02407. 68(6): 6252-6269.

(4) Ya Zhang^#, Yufan Fan^#, Yun-Qing Song^#, Guanghao Zhu^#, Xin-Juan Li^#, Jian Huang, Xinrui Guo, Changhai Luan, Dongning Kang, Lu Chen, Zhanping Xiao, Zhaobin Guo, Hairong Zeng^*, Dapeng Chen^*, Zhipei Sang^*, Guangbo Ge^*. Discovery of orally active and serine-targeting covalent inhibitors against hCES2A for ameliorating irinotecan-triggered gut toxicity. Acta Pharmaceutica Sinica B, 2025, 15(10):5312-5326 (Front cover article)

(5) Zhipei Sang^#, Shuheng Huang^#, Wanying Tan^#, Yujuan Ban^#, Keren Wang, Yufan Fan, Hongsong Chen, Qiyao Zhang, Chanchan Liang, Jing Mi, Yunqi Gao, Ya Zhang, Wenmin Liu, Jianta Wang, Wu Dong*, Zhenghuai Tan*, Lei Tang*, Haibin Luo. Discovery of novel butyrylcholinesterase inhibitors for treating Alzheimer’s disease. Acta Pharmaceutica Sinica B, 2025, 15(4): 2134-2155.

(6) Zhipei Sang^#, Ya Zhang^#, Yufan Fan^#, Changhai Luan, Zhengwei Liu, Qiyao Zhang, Hairong Zeng*, Yunqing Song*, Shuheng Huang*, Guangbo Ge*. AI-driven discovery of highly specific and efficacious hCES2A inhibitors for ameliorating irinotecan-triggered gut toxicity. Journal of Medicinal Chemistry, 2025, 68(6): 6252-6269.

(7) Zhipei Sang^#, Teng Xue^#, Qianru Xing^#, Qiyao Zhang, Hongsong Chen, Xue Wang, Furong Zhang, Wenling Fu, Wu Dong, Shuheng Huang^*, Yiyou Huang^*, Haibin Luo^*. Discovery of α-mangostin derivatives as novel PDE4 inhibitors for the treatment of Alzheimer's disease: An artificial intelligence-driven synergized strategy. Chinese Chemical Letters, 2025, https://doi.org/10.1016/j.cclet.2025.111318.

(8) Qiyao Zhang#, Yuting Li#, Qishun Jin#, Zhengwei Liu#, Hongsong Chen, Jingqi Huang, Taoyi Liu, Xiaojuan Liu, Zhenghuai Tan, Shuheng Huang*, Wu Dong*, Zhipei Sang*. Artificial intelligence-driven development of natural multi-target derivatives with BuChE inhibitory activity for treating Alzheimer's disease. Chinese Chemical Letters, 2025, doi: 10.1016/j.cclet.2025.110964.

(9) Tiancheng Sun, Zhonghua Li^*, Bingyu Xiao, Jige Yang, Mengyu Han, Jiaxin Zhang, Sijia Liu, Jinlian Ma, Zhipei Sang^*, Pan Wang^*. Recent development in PDE4D-targeted inhibitors for Alzheimer's disease therapy. European Journal of Medicinal Chemistry. 2025, 302(Pt 3): 118383.

(10) Yuting Li^#, Qiyao Zhang^#, Xinxin Wang^#, Zhengwei Liu^#, Hongsong Chen, Zhenhui Su, Yidan Xu, Weichang Zhang, Yulu Du, Zhenghuai Tan, Shuheng Huang^*, Wenmin Liu^*, Zhipei Sang^*. Development of novel rivastigmine derivatives as selective BuChE inhibitors for the treatment of AD. Bioorganic Chemistry, 2025, 157: 108245.  

(11) Jia C^#, Chai J^#, Zhang S^#, Sun Y, He L, Sang Z^*, Chen D^*, Zheng X^*. The Advancements of Marine Natural Products in the Treatment of Alzheimer's Disease: A Study Based on Cell and Animal Experiments. Mar Drugs. 2025, 23(3): 91.

(12) Zhou Y^#, Sang Z^#, Xu C, Cao Z, Xiao K, Jia Q, He Y, Luo H, Huang S. MolMod: a molecular modification platform for molecular property optimization via fragment-based generation. Mol Divers. 2025 Sep 4. doi: 10.1007/s11030-025-11342-z.

(13) Du K^#, Wang X^#, Bai Y^#, Zhang X, Xue J, Li S, Xie Y^*, Sang Z^*, Tang Y^*, Wang X^*. Development of benzimidazole-based compounds as novel capsid assembly modulators for the treatment of HBV infection. European Journal of Medicinal Chemistry. 2024, 271: 116402.

(14) Rui Chen^#, Xinjuan Li^#, Hongsong Chen^#, Keren Wang^#, Teng Xue, Jing Mi, Yujuan Ban, Gaofeng Zhu, Yi Zhou, Wu Dong^*, Lei Tang^*, Zhipei Sang^*. Development of the “hidden” multi-target-directed ligands by AChE/BuChE for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry. 2023, 251: 115253.

(15) Hongsong Chen^#, Jing Mi^#, Sen Li^#, Zhengwei Liu, Jing Yang, Rui Chen, Yujie Wang, Yujuan Ban, Yi Zhou^*, Wu Dong^*, Zhipei Sang^*. Design, synthesis and evaluation of quinoline-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023, 38(1): 2169682.  

(16) Zhou Yi^#, He Ying^#, Xue Teng^#, Mi Jing, Yang Jing, Wei Rongrui, Liu Wenmin^*, Ma Qinge^*, Tan Zhenghuai^*, Zhipei Sang^*. Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023, 38(1): 2231661.

(17) Wei RR, Lin QY, Adu M, Huang HL, Yan ZH, Shao F, Zhong GY, Zhang ZL^*, Sang ZP^*, Cao L^*, Ma QG^*. The sources, properties, extraction, biosynthesis, pharmacology, and application of lycopene. Food & Function. 2023, 14(22): 9974-9998.  

(18) Ma Qinge^*, Chen Jie, Chen Lihua, Wu Guang, Zhu Meining, He Nengxin, Wang Qinyuan, Sang Zhipei^*, Zhu Caiqing, Wu Yongzhong, Wei Rongrui^*. Citrus medica var. Sarcodactylus (Siebold ex Hoola van Nooten) Swingle: an insight into its botany, traditional uses, phytochemistry, and pharmacological properties. Phytochemistry Reviews. 2023, 22(5): 1-33.

(19) Ma Qinge, He Nengxin, Huang Huilian, Fu Xiaomei, Zhang Zhongli, Shu Jicheng, Wang Qinyuan, Chen Jie, Wu Guang, Zhu Meining, Sang Zhipei^*, Cao Lan^*, Wei Rongrui^*. Hippophae rhamnoides L.: A Comprehensive Review on the Botany, Traditional Uses, Phytonutrients, Health Benefits, Quality Markers, and Applications. Journal of Agricultural and Food Chemistry. 2023, 71(12): 4769-4788.

(20) Zhipei Sang^#,*, Keren Wang^#, Jianghong Dong^#, Lei Tang^*. Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress. European Journal of Medicinal Chemistry. 2022, 238: 114464.

(21) Zhipei Sang^#,*, Ping Bai^#, Yujuan Ban^#, Keren Wang^#, Anguo Wu, Jing Mi, Jiaqi Hu, Rui Xu, Gaofeng Zhu, Jianta Wang, Jiquan Zhang, Changning Wang^*, Zhenghuai Tan^*, Lei Tang^*. Novel donepezil-chalcone-rivastigmine hybrids as potential multifunctional anti-Alzheimer's agents: Design, synthesis, in vitro biological evaluation, in vivo and in silico studies. Bioorganic Chemistry. 2022, 127: 106007.

(22) Zhipei Sang, Qing Song, Zhongcheng Cao, Yong Deng, Li Zhang^*. Design, synthesis, and evaluation of chalcone-Vitamin E-donepezil hybrids as multi-target-directed ligands for the treatment of Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022, 37(1): 69-85.

(23) Gaofeng Zhu^#, Ping Bai^#, Keren Wang^#, Jing Mi, Jing Yang, Jiaqi Hu, Yujuan Ban, Rui Xu, Rui Chen, Changning Wang^*, Lei Tang^*, Zhipei Sang^*. Design, synthesis, and evaluation of novel O-alkyl ferulamide derivatives as multifunctional ligands for treating Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022, 37(1): 1375-1388.

(24) Chan Liu^#, Zhipei Sang^#, Hong Pan, Qin Wu, Yu Qiu^*, Jingshan Shi^*. A novel multifunctional 5,6-dimethoxy-indanone-chalcone-carbamate hybrids alleviates cognitive decline in Alzheimer's disease by dual inhibition of acetylcholinesterase and inflammation. Frontiers in Aging Neuroscience. 2022, 14: 922650.

(25) Jing Yang^#, Yi Zhou^#, Yujuan Ban^#, Jing Mi, Ying He, Xinjuan Li, Zhengwei Liu, Keren Wang, Gaofeng Zhu, Wenmin Liu, Zhenghuai Tan^*, Zhipei Sang^*. Development of naringenin-O-alkylamine derivatives as multifunctional agents for the treatment of Alzheimer’s disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022, 37(1): 792-816.

(26) Ma Qinge, Guan Yang, Sang Zhipei^*, Dong Jianghong, Wei Rongrui^*. Isolation and characterization of auronlignan derivatives with hepatoprotective and hypolipidemic activities from the fruits of Hippophae rhamnoides L. Food & Function. 2022, 13(14):7750-7761.

(27) Zhipei Sang^*,#, Qing Song, Zhongcheng Cao, Yong Deng, Zhenghuai Tan, Li Zhang^*. Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease. European Journal of Medicinal Chemistry. 2021, 216: 113310.

(28) Zhipei Sang^*,#, Jian Shi^#, Yi Zhou, Keren Wang, Yiyang Zhao, Qingfeng Li , Zhanpin Qiao, Anguo Wu^*, Zhenghuai Tan^*, Wenmin Liu^*. Development of genistein-O-alkylamines derivatives as multifunctional agents for the treatment of Alzheimer's disease. Bioorganic Chemistry. 2021, 107: 104602.

(29) Keren Wang^#, Jian Shi^#, Yi Zhou, Ying He, Jing Mi, Jing Yang, Shuang Liu, Xiangcheng Tang, Wenmin Liu, Zhenghuai Tan^*, Zhipei Sang^*. Design, synthesis and evaluation of cinnamic acid hybrids as multi-target-directed agents for the treatment of Alzheimer’s disease. Bioorganic Chemistry. 2021, 112：104879.

(30) Zhipei Sang^*,#, Keren Wang^#, Ping Bai^#, Anguo Wu, Jian Shi, Wenmin Liu, Gaofeng Zhu, Yiling Wang, Yu Lan, Zude Chen, Yiyang Zhao, Zhanpin Qiao, Changning Wang^*, Zhenghuai Tan^*. Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2020, 194: 112265.

(31) Zhipei Sang^*,#, Keren Wang^#, Jian Shi, Wenmin Liu, Xinfeng Cheng, Gaofeng Zhu, Yiling Wang, Yiyang Zhao, Qiao Zhanpin, Anguo Wu^*, Zhenghuai Tan^*. The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2020, 192: 112180.

(32) Zhipei Sang^*,#, Keren Wang^#, Jian Shi, Xinfeng Cheng, Gaofeng Zhu, Rongrui Wei, Qinge Ma, Lintao Yu, Yiyang Zhao, Zhenghuai Tan^*, Wenmin Liu^*. Apigenin-rivastigmine hybrids as multi-target-directed ligands for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2020, 187: 111958.

6.2代表性论文（2020年之前）

(1) Sang Zhipei^*,#, Wang Keren^#, Zhang Pengfei, Shi Jian, Liu Wenmin^*, Tan Zhenghuai^*. Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2019, 180: 238-252.

(2) Sang Zhipei^*,#, Wang Keren^#, Shi Jian, Liu Wenmin^*, Tan Zhenghuai^*. Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2019, 178: 726-739.

(3) Bai Ping^#, Wang Keren^#, Zhang Pengfei^#, Shi Jian, Cheng Xinfeng, Zhang Qi, Zheng Cheng, Yang Jian, Lu Xiaoxia^*, Sang Zhipei^*. Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer’s disease. European Journal of Medicinal Chemistry, 2019, 183: 111737.

(4) Sang Zhipei^*,#, Wang Keren^#, Han Xue, Cao Mengxiao, Tan Zhenghuai^*, Liu Wenmin^*. Design, synthesis and evaluation of novel ferulic acid derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease. ACS Chemical Neuroscience. 2019, 10(2): 1008-1024.

(5) Sang Zhipei^*, Pan Wanli, Wang Keren, Ma Qinge, Yu Lintao, Yang Yan, Bai Ping, Leng Chaoliang, Xu Qian, Li Xiaoqing, Tan Zhenghuai, Liu Wenmin^*. Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivativesas potential multifunctional agents for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2017, 130: 379-392.

(6) Sang Zhipei^#, Qiang Xiaoming ^#, Li Yan, Xu Rui, Xu Zhongcheng, Song Qing, Wang Ting, Zhang Xiaoyu, Liu Hongyan, Tan Zhenghuai^*, Deng Yong^*. Design, synthesis and evaluation of scutellarein-O-acetamidoalkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 135: 307-323.

(7) Zhipei Sang^#, Xiaoming Qiang^#, Yan Li^#, Wen Yuan, Qiang Liu, Wei Ang, Yikun Shi, Youfu Luo, Zhenhuai Tan^*, Yong Deng^*, Design, synthesis and evaluation of scutellarein-O-alkylamines as potent multifunctional anti-Alzheimer’s disease agents for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2015, 94: 348-366.

(8) Xiaoming Qiang^#, Zhipei Sang^#, Wen Yuan, Yan Li, Qiang Liu, Ping Bai, Yikun Shi, Wei Ang, Zhenhuai Tan^*, Yong Deng^*, Design, synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2014, 76: 314-331.

6.3 已授权代表性发明专利

(1) 桑志培; 王柯人；柳文敏；时健；程新峰；于林涛. 一种2’-羟基-3苯基苯丙酮化合物及其制备方法和用途. 2022.01.07. 中国 ZL2019106197603.

(2) 桑志培; 王柯人; 柳文敏; 于林涛; 时健; 马倩文; 王慧娟.一种茚酮查尔酮氨基甲酸酯类化合物及其制备方法和用途. 2021.03.30. 中国ZL2019101892884.

(3) 桑志培; 王柯人; 柳文敏; 于林涛; 时健; 程新峰；马倩文. 一种4-氨基甲酸酯-肉桂酰胺-4-苄基哌啶类化合物及其制备方法和用途. 2020.11.03. 中国ZL2019100795872.

(4) 桑志培; 王柯人; 柳文敏; 程新峰; 时健; 于林涛; 冉亚文. 一种芹菜素-O-烷基胺类化合物、制备方法和应用. 2020.06.26. 中国ZL2019100960136. (已转让)

七、指导本科生获得成果奖励（本人作为指导老师）：

7.1 指导本科生发表文章

(1) Zhipei Sang^#, Teng Xue^#, Qianru Xing^#(邢倩茹), Qiyao Zhang, Hongsong Chen, Xue Wang, Furong Zhang, Wenling Fu, Wu Dong, Shuheng Huang^*, Yiyou Huang^*, Haibin Luo^*. Discovery of α-mangostin derivatives as novel PDE4 inhibitors for the treatment of Alzheimer's disease: An artificial intelligence-driven synergized strategy. Chinese Chemical Letters, 2025, https://doi.org/10.1016/j.cclet.2025.111318. (中科院大类一区，IF = 9.4，2022级药学本科生邢倩茹为共同第一作者）

(2) Qiyao Zhang^#, Yuting Li^#, Qishun Jin^#(金琪顺), Zhengwei Liu^#, Hongsong Chen, Jingqi Huang, Taoyi Liu, Xiaojuan Liu, Zhenghuai Tan, Shuheng Huang*, Wu Dong*, Zhipei Sang^*. Artificial intelligence-driven development of natural multi-target derivatives with BuChE inhibitory activity for treating Alzheimer's disease. Chinese Chemical Letters, 2026, 37, 110964. (中科院大类一区，IF = 9.4，2024级药学本科生金琪顺为共同第一作者)

(3) Yuting Li^#, Qiyao Zhang^#, Xinxin Wang^#(王馨莘), Zhengwei Liu^#, Hongsong Chen, Zhenhui Su, Yidan Xu, Weichang Zhang, Yulu Du, Zhenghuai Tan, Shuheng Huang^*, Wenmin Liu^*, Zhipei Sang^*. Development of novel rivastigmine derivatives as selective BuChE inhibitors for the treatment of AD. Bioorganic Chemistry, 2025, 157: 108245. (中科院大类二区，IF = 4.5，2022级药学本科生王馨莘为共同第一作者)

(4) Zhengwei Liu^#, Xinjuan Li^#, Mengqi Huang^#(黄梦琪), Zhenhui Su, Qiyao Zhang, Yuting Li, Yi Zhou, Lintao Yu, Wenmin Liu*, Zhipei Sang*. Development of novel fluoro-substituted rivastigmine derivatives as selective AChE inhibitors for the treatment of AD. Medicinal Chemistry Research, 2024, 33(7):1-10 (中科院大类四区，IF = 3.1，2021级药学本科生黄梦琪为共同第一作者)

7.2 指导本科生获批项目

(1) 海南大学2025年大学生创新训练计划项目省级立项，“基于脑靶向的新型高选择性BuChE抑制剂的设计、合成及抗阿尔茨海默症研究”，项目负责人：2024级药学刘陶怡

(2) 海南大学2023年大学生创新创业计划项目国家级立项，新型BuChE抑制剂的设计、成药性优化及抗AD活性研究，项目编号：202310589011，项目负责人：2021级药学苏祯惠

(3) 海南大学2023年大学生创新创业计划项目国家级立项，新型倒捻子素的设计、合成及其抗肺纤维化活性研究，项目编号：202310589063，项目负责人：2022级药学邢倩茹

(4) 海南大学药学院2025年度本科生课外科研课题立项，项目负责人：2024级药学刘晓娟

(5) 海南大学药学院2024年度本科生课外科研课题立项，项目负责人：2022级药学王馨莘

(6) 海南大学药学院2023年度本科生课外科研课题立项，项目负责人：2021级药学苏祯惠

7.3指导本科生获奖情况

(1) 第十九届“挑战杯”中国移动全国大学生课外学术科技作品竞赛主体赛中荣获“三等奖”一项，项目负责人：2024级药学金琪顺，（参与人：2022级药学王馨莘、2022级药学黄镜琦、2023级药学徐乙丹、2023级食品李家和、2023级化学王米乐、2022级药学邢倩茹、2023级药学杨坤坤），2025年11月，第一指导教师

(2) 第十二届“挑战杯”海南省大学生课外学术科技作品竞赛中荣获“特等奖”一项，项目负责人：2024级药学金琪顺，（参与人：2022级药学黄镜琦、2023级化学王米乐、2023级食品李家和），2025年6月，第一指导教师

(3) 第十二届“挑战杯”海南省大学生课外学术科技作品竞赛中荣获“二等奖”一项，项目负责人：2023级药学徐乙丹（参与人：2022级药学王馨莘、2023级药学张维昌、2023级药学杜雨露、2024级人文地理与城乡规划闫靖旋、2024级药学韦珍视、2024级药学刘陶怡），2025年6月，第一指导教师

(4) 第十五届“挑战杯”河南省大学生课外学术科技作品竞赛中荣获“二等奖”两项，2021.06，第一指导教师

(5) 第十三届“挑战杯”河南省大学生课外学术科技作品竞赛二等奖，2017.08.10，第一指导教师

(6) 第八届“国药工程—东富龙杯”全国大学生制药工程设计竞赛二等奖，2018.08，第二指导教师

欢迎本科生参与课题组科研课题！

欢迎有药学、生物学、化学等相关学科背景的同学报考本课题组的博士/硕士研究生!